BCAB NASDAQ
BioAtla, Inc.
1W: -25.4%
1M: -63.6%
3M: -61.9%
YTD: -95.3%
1Y: -95.3%
3Y: -99.0%
5Y: -99.9%
$1.74
Last traded 2026-09-08 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships13
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2022-01-11
Earliest Filing
2025-12-31
Latest Filing
partner: 8
investor: 5
Counterparties (Filed by BCAB)
13 relationshipsCompanies named in BCAB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Inversagen AI, LLC | — | investor | Investor entering into an Investment Agreement to purchase SPV common units for $40 million | 2025-12-31 | View |
| Alliance International Resources Corp. | — | investor | Lead investor in the initial closing of the SPV investment | 2025-12-31 | View |
| Inversagen, LLC | — | partner | Co-owner of Inversagen AI, LLC and holder of exclusive license to CAB senescence technologies | 2025-12-31 | View |
| GATC Health Corp | — | partner | Co-owner of Inversagen AI, LLC and holder of exclusive rights to senescence AI longevity technologies | 2025-12-31 | View |
| Yorkville | MCGAU | investor | Investor in Pre-Paid Advance Agreements and counterparty to Standby Equity Purchase Agreement | 2025-11-21 | View |
| Anson Investments Master Fund LP | — | investor | Investor in Pre-Paid Advance Agreements | 2025-11-21 | View |
| Anson East Master Fund LP | — | investor | Investor in Pre-Paid Advance Agreements | 2025-11-21 | View |
| Tungsten Partners LLC | — | partner | Placement agent for the Agreements | 2025-11-21 | View |
| Context Therapeutics Inc. | CNTX | partner | Entered into a license agreement granting BioAtla an exclusive worldwide license to develop and commercialize two antibo | 2024-09-23 | View |
| Himalaya Therapeutics SEZC | — | partner | Entered into a Global Transaction Agreement consenting to BioAtla's license with Context and receiving a share of paymen | 2024-09-23 | View |
| Jefferies LLC | JEF | partner | Sales agent for BioAtla, Inc.'s open market sale of common stock. | 2023-01-06 | View |
| Bristol-Myers Squibb Company | BMY | partner | Clinical trial collaboration and supply agreement for combination therapies | 2022-01-11 | View |
| BioDuro-Sundia | — | partner | Provider of preclinical development services | 2022-01-11 | View |
Mentioned As Counterparty
1 mentionsOther companies that named BCAB in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Officer/Director Change; Exhibits | View | |
| 2026-08-28 | Delisting Notice | View | |
| 2026-07-16 | Shareholder Vote | View | |
| 2026-04-02 | Other Events; Exhibits | View | |
| 2026-03-31 | Earnings Release; Regulation FD | View | |
| 2026-03-23 | Officer/Director Change; Shareholder Vote | View | |
| 2026-03-02 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; De | View | |
| 2026-02-09 | Other Events | View | |
| 2026-02-06 | Notice of Delisting or Transfer; Regulation FD Disclosure | View | |
| 2026-01-30 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2026-01-12 | Unregistered Sales of Equity Securities; Amendments to Articles of Incorporation or Bylaws; Submissi | View | |
| 2025-12-31 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-12-30 | Submission of Matters to a Vote of Security Holders; Other Events | View | |
| 2025-11-21 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-22 | Other Events | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-20 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-16 | Notice of Delisting or Transfer | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR